Back to Forecasting
IBRXActive

Will the FDA provide a clear regulatory pathway for ANKTIVA in NSCLC by December 31, 2026?

Resolves January 15, 2027(261d)
IG: 0.48

Current Prediction

32%
Likely No
Model Agreement92%
Predictions9 runs
Last UpdatedApril 19, 2026

Prediction History

Initial
38%
Mar 17
-6pp
Current
32%
Apr 19
Q1 2026 preliminary release contained no US NSCLC pathway update. Company bandwidth is focused on BCG-naive sBLA. March 24 FDA warning letter creates tone-of-interaction headwind for new indication discussions.

Baseline 0.38 reflected management's stated intent to pursue US NSCLC discussions in 2026. Absent Q1 progress and with the warning letter overhang, timing pressure on H2 2026 increases. Nudged down to 0.32.

Why This Question Matters

US NSCLC represents the largest potential expansion market for ANKTIVA. The Regulatory Reader noted discussions planned for 2026 but no formal pathway established. FDA clarity on NSCLC would materially de-risk the multi-indication thesis. Absence of progress would narrow the growth narrative to bladder cancer only.

REGULATORY_EXPOSURECOMPETITIVE_POSITION

Prediction Distribution

0%25%50%75%100%
opus
sonnet
haiku
Range: 30%35%Aggregate: 32%
Individual Predictions(9 runs)
opusRun 1
32%

No Q1 update on US NSCLC pathway. Management bandwidth is focused on BCG-naive sBLA (higher-value near-term catalyst). The FDA warning letter creates a cooler regulatory tone that could delay a meeting or pathway disclosure. Probability lowered modestly from baseline 0.38.

No Q1 updateBCG-naive absorbs bandwidthWarning letter tone effect
opusRun 2
30%

The resolution criteria require a formal disclosure by year-end (IND, sNDA, BLA, or published meeting minutes). Without Q1 progress, the runway for H2 2026 action is narrowing. Saudi approval is helpful precedent but does not translate to US pathway.

Narrowing H2 runwayNo US precedentSaudi approval limited relevance
opusRun 3
35%

Company's multi-indication ambitions remain real. An FDA Type B or C meeting on NSCLC pathway could be disclosed later in 2026. But the warning letter and focus on bladder expansion argue for slippage into 2027.

Multi-indication ambition realPossible Type B/CSlippage risk to 2027
sonnetRun 1
34%

Baseline 0.38 was predicated on 'discussions planned for 2026.' No Q1 progress modestly reduces probability. Warning letter adds a small additional drag.

No Q1 progressModest warning letter drag
sonnetRun 2
30%

The resolution criteria are specific (IND acceptance, sNDA, BLA, or meeting minutes). Less formal pathway communications may occur but wouldn't resolve YES. Base rate for meeting disclosure of this specificity in a given calendar year: ~30%.

Specific criteriaInformal communications don't resolve30% base rate
sonnetRun 3
33%

Probability shifts modestly lower with Q1 no-update, offset partially by possibility the company accelerates NSCLC discussions post-BCG-naive sBLA submission if that goes well.

Q1 no-update dragPost-sBLA acceleration possible
haikuRun 1
32%

No Q1 progress. Warning letter headwind. Probability ~32%.

No progressWarning letter
haikuRun 2
30%

Specific criteria + competing priorities = moderate-low probability.

Specific criteriaCompeting priorities
haikuRun 3
34%

Still possible but less likely than baseline.

Still possibleLess likely

Resolution Criteria

Resolves YES if ImmunityBio publicly discloses FDA acceptance of an IND, sNDA, BLA submission, or published meeting minutes confirming a clear pathway (accelerated approval, breakthrough therapy designation, etc.) for ANKTIVA in NSCLC by December 31, 2026.

Resolution Source

ImmunityBio press releases, 8-K filings, or FDA meeting minutes

Source Trigger

US FDA pathway decision for NSCLC indication

regulatory-readerREGULATORY_EXPOSUREHIGH
View IBRX Analysis

Full multi-lens equity analysis